FABRAZYME® (Agalsidase beta) is used in the treatment of Fabry Disease by replacing a missing enzyme that lowers the amount of GL-3 being deposited in the lining of blood vessels.
FABRAZYME® is manufactured by Sanofi Genzyme.
Administration and Dosage:
Administration of FABRAZYME® is by bi-weekly intravenous infusion.
Common Side Effects:
The more common side effects of FABRAZYME® include severe allergic (anaphylaxis) and hypersensitivity reactions, infusion-associated reactions, upper respiratory tract infection, chills, fever, headache, cough, burning and/or tingling sensation, fatigue, swelling in the legs, dizziness and rash.
More information:
Please read the full Prescribing Information for FABRAZYME® and discuss any questions you have with your doctor.
Indication:
FABRAZYME® is indicated to treat:
Fabry Disease
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Check our Privacy Practice